Figure 1.
FDA approval timeline of immune checkpoint inhibitors for the treatment of malignancies (https://www.fda.gov/drugs, retrieved Mar 7, 2018). Abbreviations: NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma; cHL, classical Hodgkin Lymphoma; SCCHN, squamous cell carcinoma of the head and neck; MCC, merkel cell carcinoma; HCC, hepatocellular carcinoma.